Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

HIVR4P 2016 is made possible in part by the generous support of the American people through 1 R13 AI122959-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services or USAID; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2016
Plenary 02: Unraveling the Mysteries of HIV Transmission
HIV Transmission Dynamics
Deenan Pillay
Africa Health Research Institute, South Africa
Mechanisms of HIV Transmission: Implications for Prevention
Julie Overbaugh
Fred Hutchinson Cancer Research Center, United States
Providing Prevention Where It Matters Most: Data-informed Targeting of HIV Prevention and Care
Patrick Sullivan
Emory University Rollins School of Public Health, United States
from HIV Research for Prevention 2016 on 18 October 2016 08:30-10:00
Oral Abstract Session 01: Antibody Epitopes: Connecting the Dots
A Prominent Site of Antibody Vulnerability on HIV Env Incorporates the CCR5 Coreceptor Site and Its Camouflaging Glycans
Devin Sok
International AIDS Vaccine Initiative (IAVI), United States
HIV-1 MPER-directed Broadly Neutralizing Antibodies from an Acute-infection Cohort RV217 Subject
Nicole A. Doria-Rose
Vaccine Research Center, NIAID, NIH, United States
Persistence of an HIV Broadly Neutralizing Antibody Lineage Despite Complete Neutralization Escape
Jinal N Bhiman
National Institute for Communicable Diseases of the National Health Laboratory Services, South Africa
Viral Escape from HIV Broadly Neutralizing Antibodies Is Slower and More Complex than for Early Strain-specific Neutralizing Antibodies
Colin Anthony
University of Cape Town, South Africa
The Anti-gp120 mAb CH58 Recognizes a Not-fully-processed Form of Surface-expressed Env
Jason Yolitz
NIAID, NIH, United States
Fusion Peptide of HIV-1 as a Site of Vulnerability to Neutralizing Antibody
Rui Kong
Vaccine Research Center, NIAID, NIH, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 02: Crossing the Border: Mechanisms of Mucosal Transmission
Defining HIV/SIV Infection after Rectal Challenge in Rhesus Macaque Model Using Dual Reporter System
Danijela Maric
Northwestern University, United States
Broadly Neutralizing Antibodies Can Prevent HIV Infection in Foreskin Ex-vivo Explant Infection Models
Maria Lemos
Fred Hutchinson Cancer Research Center, United States
In Vivo Analysis of Fluorescently Tagged HIV-specific and Non-specific Antibodies in Non-human Primates
Ann M. Carias
Northwestern University, United States
HIV Susceptibility in CD4+ T Cells Derived from the Inner Versus Outer Foreskin
Ronald Galiwango
University of Toronto, Canada
Intestinal Dendritic Cells and Macrophages Differentially Affect HIV-1 Transmission Across the Intestinal Mucosa
Mariangela Cavarelli
CEA, France
Levels of Immune Activation in Cervical Cells, Rectal Cells and PBMCs Isolated from a Kenyan Women Cohort at Low-risk of HIV Acquisition
Catia Perciani
University of Toronto, Canada
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 03: PrEP Problems: Real and Imagined
The Effect of Oral Pre-exposure Prophylaxis on the Progression of HIV-1 Seroconversion
Deborah Donnell
Fred Hutchinson Cancer Research Center, United States
Infant Exposure to Tenofovir and Emtricitabine through Breast Milk when Used as Pre-exposure Prophylaxis by HIV-uninfected Lactating Women
Kenneth Mugwanya
University of Washington, United States
HIV-1 Resistance Outcomes in Seroconverters from the MTN-020/ASPIRE Dapivirine Vaginal Ring Study
Urvi M. Parikh
University of Pittsburgh, United States
Evaluation of Resistance to Cabotegravir Long-acting (CAB LA) in SIVmac251-infected Macaques
Chasity Andrews
Aaron Diamond AIDS Research Center, United States
The Potential for Condom Ideology to Cloud Clinical Judgment around Prescribing HIV Pre-exposure Prophylaxis (PrEP)
Sarah K. Calabrese
Yale School of Public Health, Yale University, United States
Newly Acquired HIV-1 Infection with Multi-Drug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP
Howard Grossman
Cleveland Clinic, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 04: It Takes Two to Tango: Host, Hormones and Drug Levels in the Mucosa
Pharmacokinetic Analysis of Tenofovir Gel Use in Pre Versus Postmenopausal Women
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Modulation of Tenofovir (TFV) Pharmacokinetics (PK) and Antiviral Activity by Vaginal Microbiota: Implications for Topical Preexposure Prophylaxis
Ekaterina Taneva
Albert Einstein College of Medicine, United States
Hypo-osmolar Formulation of TFV Enemas Promotes Uptake and Transformation of TFV to TFV-DP in Tissues and Prevents SHIV/SIV Infection
Francois Villinger
University of Louisiana at Lafayette, United States
Use of Injectable Depot Medroxyprogesterone Acetate (DMPA) Downregulates Cervicovaginal Epithelial Barrier Genes - Similarly to Mucosal Inflammation
Irina A Zalenskaya
CONRAD, Eastern Virginia Medical School, United States
Microbiome Composition and Function Drives Wound-healing Impairment in the Female Genital Tract
Irene Xie
Public Health Agency of Canada, Canada
MPA Has Minimal Impact on HIV-1 Replication in Ectocervical Tissue Ex Vivo
Hawa Mariko
University of Pittsburgh, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 05: Risky Business
Behavioral and Biological Risk Factors among MSM in Kigali, Rwanda
Julien Nyombayire
Project San Francisco, Rwanda Zambia HIV Research Group, Rwanda
Meta-analysis and Modelling Study of Anal Sex Practices and Its Contribution to HIV Incidence among High-risk Women Across Twenty US Cities
Jocelyn Elmes
Imperial College London, United Kingdom
A Validated Risk Score to Predict HIV Acquisition in African Women: Assessing Risk Score Performance among Women who Participated in the ASPIRE Trial
Jennifer Balkus
Fred Hutchinson Cancer Research Center, United States
HIV Incidence Factors and Trends in Voluntary Counseling and Testing, Silom Community Clinic, Bangkok, Thailand, 2005-2015
Wipas Wimonsate
Thailand MOPH - U.S. CDC Collaboration, Thailand
Bacterial Vaginosis Associated Microbes Induce Altered Innate Immune Profiles
Ryan Cheu
University of Washington, United States
HIV Treatment Cascade among Transgender Women: Population-estimates from Rio de Janeiro, Brazil
Beatriz Grinsztejn
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 06: Of Mice and (Wo)men: Pharmacokinetics/Pharmacodynamics of Novel Products
Vaginal Transmission of WT or Resistant HIV-1 Was Not Inhibited by Long Acting Rilpivirine at High Plasma and Genital Concentrations in BLT Mice
Zandrea Ambrose
University of Pittsburgh School of Medicine, United States
Pharmacokinetics and Safety of Pod-intravaginal Rings Delivering VRC01-N for HIV Prophylaxis in a Macaque Model
John Moss
Oak Crest Institute of Science, United States
Pharmacokinetic Profile of Lamivudine (3TC) in Macaques and Relative Drug Exposure in Rectal and Vaginal Tissues
Ivana Massud
Centers for Disease Control and Prevention, United States
Comparison of Safety and Pharmacokinetics of Vaginal Rings Releasing Tenofovir Disoproxil Fumarate Alone and with Emtricitabine in Sheep and Humans
Kathleen Vincent
University of Texas Medical Branch, United States
Clinical Performance, Acceptability, and Optimization of Fast-dissolve Vaginal Inserts Designed for HIV-prevention: Results from Two Clinical Studies
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Assessment of the Potential for Pharmacodynamic Interaction Between Dapivirine and Levonorgestrel When Co-administered in an MPT Vaginal Ring
Jonathon Holt
International Partnership for Microbicides, United States
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 07: Through the Looking Glass: New Insights into Mucosal Biology
The Role of Gut Homing Receptor α4β7 in HIV Pathogenesis and Transmission - a Prospective Cohort Study
Aida Sivro
Center for AIDS Programme of Research in South Africa, South Africa
Immuno-PET/CT Imaging Reveals Differences in Virus and CD4+ Cell Localization in SIV Infected Rhesus Macaques Treated with an Anti-α4β7 mAb
James Arthos
NIAID, NIH, United States
Multivalent Immunoglobulin Muc5AC Complexes Enhance Antibody Potency Against HIV-1
Arangassery Rosemary Bastian
Northwestern University, United States
Semen Demons: Immunosuppressive Factors Within Semen Modulate Anti-HIV-1 Cellular Immune Responses
Kevin John Selva
University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia
Antiretroviral Therapy Contributes to Intestinal Immune Dysfunction in Healthy Macaques
Alexandra Ortiz
LPD, NIAID, NIH, United States
Initiation of c-ART During HIV Primary Infection Maintains HIV-specific Memory B Cells and Tfh Cells in the Gut Mucosa
Cyril Planchais
INSERM U955, Team 16, Vaccine Research Institute (VRI), France
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 08: A Sugar Coated Pill: Immunogenicity of Envelope
Potent HIV Neutralizing Antibodies Elicited by BG505 SOSIP Trimer Immunization in Rhesus Macaques as a Starting Point for Iterative Vaccine Design
Marit van Gils
Academic Medical Center, University of Amsterdam, Netherlands
Priming a VRC01-like Antibody Response in Human Immunoglobulin Locus Transgenic Mice
Devin Sok
International AIDS Vaccine Initiative (IAVI), United States
Induction of Cross-clade Reactive, Functional Antibodies with Immunogens Targeting the V2 Region of HIV
Rebecca Powell
Icahn School of Medicine at Mount Sinai, United States
Rationally Designed Immunogens Induce Antibody Responses Targeting Polymorphic Forms of gp120 V1V2
Xunqing Jiang
New York University School of Medicine, United States
An Adenovirus 26 Vaccine Expressing Clade A Env (Ad26.EnvA) Does Not Elicit Diversionary gp41-specific Antibodies in Humans
Helen D'Couto
Beth Israel Deaconess Medical Center, United States
MVA-expressed gp140 Boosts More Durable V1/V2 and gp120 Antibody Responses than gp120 Protein in Alum
Xiaoying Shen
Duke Human Vaccine Institute, United States
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Symposium 01: Vaccine-Induced Humoral Immunity
Initiation of Neutralizing Antibody B Cell Lineages by HIV Vaccine Candidates
Barton Haynes
Duke University, United States
Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers
Christopher Parks
The International AIDS Vaccine Initiative, United States
Towards a Global HIV Vaccine: (Pre)-Clinical Evaluation of Prime-Boost Regimens Using Ad26 and MVA with Mosaic Antigens and Soluble Gp140 Proteins
Hanneke Schuitemaker
Janssen Vaccine and Prevention, Netherlands
Defining Correlates of Protective Humoral Immunity against HIV
Galit Alter
Ragon Institute of MGH, MIT and Harvard, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 02: The Role of Mucosal Barriers and Targets in HIV Acquisition
A Central Role for α4β7+ CD4+ T Cells in HIV Transmission and Pathogenesis
Claudia Cicala
National Institute of Allergy and Infectious Diseases, NIH, United States
Effects of Sex Hormones and Vaginal Microbiota on the Cervicovaginal Mucosal Barrier
Janneke van de Wijgert
University of Liverpool, United Kingdom
Tissue Compartmentalization of Human Immune Responses
Donna Farber
Columbia University Medical Center, United States
Vaginal Bacteria modulate HIV Pre-exposure Prophylaxis Efficacy in Women
Adam Burgener
Public Health Agency of Canada, Canada
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 03: Choosing ARVs for Prevention: Ensuring and Measuring Effective Tissue Delivery
Location, Location, Location: Pharmacology and Tissue Delivery of ARVs
Angela Kashuba
University of North Carolina, United States
Issues with Administration Route as It Relates to Participant Preference, Dosing Strategies, and Coverage Around Times at Risk
Julie Fox
United Kingdom
Pharmacologic Approaches to Assess Adherence
Peter Anderson
University of Colorado, Denver, United States
Linking PK and PD: Choosing Drugs and Predicting Clinical Outcomes Using Data from Explant Models, Animal Models
Jim Turpin
Division of AIDS, NIAID, NIH, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 04: Adolescents: Bodies, Brains and Behaviors
Research Gaps in Understanding Sex Steroid Hormones and Biological and Immunological Features that May Impact Susceptibility to HIV
Sharon L. Achilles
University of Pittsburgh, United States
Promoting Resilience: Understanding Implications of Psychological Development and Decision-making
Susan Rosenthal
Columbia University Medical Center, United States
How to Talk to Me about Sex
Two Youth from Chicago - Kortez Davis and Sydney Roberson
United States
What Interventions Are Suitable for Adolescents?
Chewe Luo
UNICEF, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2016